Predictive potential and need for standardization of PD-L1 immunohistochemistry.

Virchows Archiv : an International Journal of Pathology
Spasenija Savic Prince, Lukas Bubendorf

Abstract

Checkpoint inhibitors targeting the PD-1/PD-L1 axis are a promising treatment option in several tumor types. PD-L1 expression detected by immunohistochemistry is the first clinically validated predictive biomarker for response to PD-1/PD-L1 inhibitors, though its predictive value varies significantly between tumor types. With the approval of pembrolizumab monotherapy for treatment-naïve, advanced non-small cell lung cancer, PD-L1 testing has to become broadly available in pathology laboratories. When PD-L1 testing started to be introduced in routine pathology practice, there were several open issues, which needed to be addressed in order to provide accurate results. This review will discuss the complex biological background of PD-L1 as predictive biomarker, summarize relevant clinical trials in NSCLC illustrating the origin of different PD-L1 expression cutoffs and scorings, and address issues important for PD-L1 testing including the analytical comparability of the different clinical trial-validated PD-L1 immunohistochemistry assays, the potential of laboratory-developed tests, and an overview of the different scoring algorithms.

References

Mar 22, 2012·Cancer Cytopathology·Tamami DendaSadahito Kuwao
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Aug 13, 2014·Cytopathology : Official Journal of the British Society for Clinical Cytology·D JainV K Iyer
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 7, 2015·Current Opinion in Pharmacology·Joel Sunshine, Janis M Taube
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jan 13, 2016·Archives of Pathology & Laboratory Medicine·Keith M Kerr, Fred R Hirsch
Jan 19, 2016·Archives of Pathology & Laboratory Medicine·Lynette M ShollUNKNOWN Members of Pulmonary Pathology Society
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe MassardNeil H Segal
Jul 9, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Andreas H ScheelReinhard Buettner
Aug 20, 2016·JAMA Oncology·Patricia GauleDavid L Rimm
Oct 25, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tzahi NeumanGilad W Vainer
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Jan 12, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marianne J RatcliffeJill Walker
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Apr 20, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wendy A CooperStephen B Fox
May 31, 2017·Journal of Midwifery & Women's Health·Mary C Brucker, Tekoa L King
Jul 12, 2017·Applied Immunohistochemistry & Molecular Morphology : AIMM·Rasmus RøgeSøren Nielsen
Aug 30, 2017·Histopathology·Andreas H ScheelJosef Rüschoff
Sep 9, 2017·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Oct 21, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Reinhard BüttnerMing-Sound Tsao
Nov 8, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Erik ThunnissenEgbert F Smit
Nov 28, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Shona HendryStephen B Fox
Jan 20, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J AdamS Lantuéjoul
Feb 7, 2018·Cancer Cytopathology·Eleanor Russell-GoldmanMarina Vivero
May 2, 2018·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Anthony W H ChanKa F To
May 20, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Louis FehrenbacherFabrice Barlesi
May 26, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ming Sound TsaoFred R Hirsch
Jul 20, 2018·Applied Immunohistochemistry & Molecular Morphology : AIMM·Maher A SughayerNaim Qamhia

❮ Previous
Next ❯

Citations

Mar 27, 2019·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Guo-Qiang ZhangQuan-Yong Luo
May 28, 2019·Virchows Archiv : an International Journal of Pathology·Spasenija SavicLukas Bubendorf
Sep 5, 2020·Cancer Cytopathology·Elena VigliarGiancarlo Troncone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Expert Review of Anticancer Therapy
Mirte MullerPaul Baas
Archives of Pathology & Laboratory Medicine
Philip T Cagle, Eric H Bernicker
BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Konstantinos Leventakos, Aaron S Mansfield
© 2022 Meta ULC. All rights reserved